**Question:** In Crigler-Najjar syndrome type II, the defect lies in

A. UDP-glucuronosyl-transerase (UGT1A1)
B. Cytochrome P450 enzymes
C. P450 oxidoreductase
D. Bilirubin transporters

**Correct Answer:** A. UDP-glucuronosyl-transerase (UGT1A1)

**Core Concept:** Crigler-Najjar syndrome is a rare genetic disorder characterized by severe neonatal hyperbilirubinemia (excessive bilirubin levels in the blood) and encephalopathy (brain damage). It is classified into two types: type I and type II.

**Why the Correct Answer is Right:** Crigler-Najjar syndrome type II is caused by a deficiency in the enzyme UDP-glucuronosyl-transerase (UGT1A1), which is responsible for conjugating bilirubin, making it water-soluble and facilitating its excretion through the liver into the bile. In type II, the enzyme deficiency leads to unmetabolized bilirubin accumulation in the blood, causing the clinical manifestations of the disorder.

**Why Each Wrong Option is Incorrect:**

B. Cytochrome P450 enzymes: These enzymes are involved in the oxidation and conjugation of various drugs and xenobiotics (foreign substances), not bilirubin conjugation.

C. P450 oxidoreductase: This enzyme is part of the cytochrome P450 system and is not directly related to bilirubin conjugation.

D. Bilirubin transporters: The defect in bilirubin transporters would result in impaired excretion of bilirubin into the bile, not its overproduction as in Crigler-Najjar syndrome.

**Clinical Pearl:** Understanding the underlying etiology of genetic disorders like Crigler-Najjar syndrome can help in diagnosing and managing such cases in clinical practice. It is crucial to differentiate between the two types (I and II) as the treatment approaches differ significantly. Type I is more severe and often requires liver transplantation, while type II can be managed with liver transplantation or hematopoietic stem cell transplantation.